Pfizer's PARP inhibitor meets in Phase III for breast cancer

Pfizer Inc. (NYSE:PFE) said once-daily oral talazoparib (MDV3800) met the primary endpoint of improving progression-free survival (PFS) in the Phase III EMBRACA trial to treat breast cancer. Specifically, talazoparib led

Read the full 307 word article

User Sign In